AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(For a full text of statement, contact www.asianet.com.au)
HELSINKI, May 31 /PRNewswire-AsiaNet/ --
New Outcomes From The Landmark XENDOS Study
Xenical(R) is significantly more effective than diet alone in reducing weight and simultaneously improving cardiovascular risk factors in patients with Metabolic Syndrome, according to new outcomes from the landmark XENDOS study, presented today at the 12th European Congress on Obesity (ECO), Helsinki, Finland.(1)
Metabolic Syndrome, otherwise known as Syndrome X or insulin resistance syndrome, describes a 'cluster' of 3 or more risk factors, such as high waist measurement, increased fasting glucose levels, abnormal blood lipid levels and high blood pressure in a single patient, leading to an increased risk of cardiovascular disease. Up to one in five people in Western countries is considered a 'cardiovascular time-bomb' because they have Metabolic Syndrome.(2)
Weight loss is the only intervention that has been shown to improve all of the cardiovascular risk factors seen in patients with Metabolic Syndrome.(3)
This new analysis from XENDOS examined the effects of treatment with Xenical in patients with Metabolic Syndrome, based on criteria from the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III)*. Forty per cent of XENDOS study participants had Metabolic Syndrome.
Source: HighBeam Research, XENICAL SIGNIFICANTLY IMPROVES METABOLIC SYNDROME ABNORMALITIES.